Sanofi Files First Biosimilar Insulin Aspart In Challenge To NovoRapid
Executive Summary
The European Medicines Agency is evaluating Sanofi's SAR341402, the first biosimilar insulin aspart product to be submitted for EU marketing authorization. If approved, the product will compete with Novo Nordisk's diabetes drug Novorapid/NovoLog.